Newron Pharmaceuticals' Evenamide Shows Promise in Schizophrenia Treatment

Newron Pharmaceuticals reports that recent research in "Neuropsychopharmacology" highlights Evenamide's potential to treat schizophrenia. This preclinical study from the University of Pittsburgh demonstrates Evenamide's effectiveness in targeting schizophrenia's core pathology in the hippocampus. The drug alleviates positive, negative, and cognitive symptoms in a schizophrenia model.

Evenamide, a first-in-class glutamate modulator, shows prolonged effects beyond drug elimination, indicating potential neuronal plasticity impact. It provides a novel approach by targeting hippocampal hyperexcitability, absent in current treatments, offering hope for treatment-resistant schizophrenia patients.

The research supports prior Phase II and III trial results, suggesting Evenamide's efficacy in improving symptoms significantly. With favorable safety profiles compared to existing antipsychotics, Evenamide could revolutionize schizophrenia treatment strategies.